HCPCS Code Descriptor:
Injection, faricimab-svoa, 0.1 mg
Route of Administration:
VABYSMO is an Opthalmic drug manufactured by Genentech and administered via the Intraocular route of administration. The J Code: J2777 is aligned to the drug VABYSMO.
Vabysmo belongs to the class of drugs known as anti-angiogenic ophthalmic agents. Vabysmo is used to treat certain eye disorders and works by stopping two disease pathways in the eye that are thought to cause instability. Vabysmo is a branded drug manufactured by Genentech USA. From July 2022 to September 2022, Vabysmo was aligned to the C Code: C9097. Beginning in October 2022, Vabysmo has been aligned to the J Code: J2777. Patient assistance programs for this medication can be found through Genentech.
Access Pricing and More By Registering
HCPCS Added Date:
HCPCS Effective Date:
HCPCS Short Description:
Inj, faricimab-svoa, 0.1mg
Billing and Coding Guide: